Clinical Trial ECOGHEME2906


Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)

Principal Investigator(s)

Stephen Strickland


  • Protocol No. ECOGHEME2906
  • Open Date: 01/20/2012
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the effect of clofarabine induction and consolidation therapy on overall survival in comparison with standard therapy (daunorubicin & cytarabine) in newly diagnosed AML patients age greater than or equal to 60 years.
  • Disease Sites: Leukemia
  • Therapies: Bone Marrow/Stem Cell Transplant; Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Clofarabine; Cytarabine (ARA-C); Daunorubicin (Daunomycin); Decitabine; Dexamethasone
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01041703
  • Secondary Protocol No: E2906



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.